Vedolizumab as a Second Line Biologic for Cronkhite Canada Syndrome and an Approach Toward Disease Monitoring
Open Access
- 1 November 2025
- journal article
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Abstract
A 62-year-old woman was diagnosed with Cronkhite-Canada Syndrome, presenting with classic clinical symptoms and endoscopic findings. She initially responded to infliximab (IFX) with symptomatic improvement, normalized calprotectin, and minimal disease activity on endoscopy for 3 years. Despite IFX trough levels appropriate for inflammatory bowel disease goals and no IFX antibodies, she subsequently lost response and had recurrence of symptoms and disease activity. She started on a course of corticosteroids, discontinued IFX, and transitioned to vedolizumab with standard induction and maintenance dose every 8 weeks, achieving clinical remission and near complete endoscopic remission.Keywords
This publication has 12 references indexed in Scilit:
- Cronkhite-Canada syndrome: treatment responses and improved overall survivalInternational Journal of Colorectal Disease, 2023
- Combination therapy in inflammatory bowel disease: Current evidence and perspectivesInternational Immunopharmacology, 2022
- Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?Diagnostics, 2022
- Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related EnteropathyClinical Gastroenterology and Hepatology, 2022
- Sustained clinical response to infliximab in refractory Cronkhite-Canada syndromeBMJ Case Reports, 2020
- Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to PathogenesisAmerican Journal of Gastroenterology, 2016
- Successful treatment of Cronkhite–Canada syndrome using anti-tumor necrosis factor antibody therapyEndoscopy, 2014
- Clinicopathologic Features and Treatment Outcomes in Cronkhite–Canada Syndrome: Support for AutoimmunityDigestive Diseases and Sciences, 2011
- The Cronkhite-Canada Syndrome. An analysis of clinical and pathologic features and therapy in 55 patients.1982
- Generalized Gastrointestinal PolyposisNew England Journal of Medicine, 1955